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Abstract
Background: Tissue factor pathway inhibitor-2 (TFPI-2) is a serine protease inhibitor that exerts multiple physiological
and patho-physiological activities involving the modulation of coagulation, angiogenesis, tumor invasion, and
apoptosis. In previous studies we reported a novel role of human TFPI-2 in innate immunity by serving as a
precursor for host defense peptides. Here we employed a number of TFPI-2 derived peptides from different
vertebrate species and found that their antibacterial activity is evolutionary conserved although the amino acid
sequence is not well conserved. We further studied the theraputic potential of one selected TFPI-2 derived
peptide (mouse) in a murine sepsis model.
Results: Hydrophobicity and net charge of many peptides play a important role in their host defence to invading
bacterial pathogens. In vertebrates, the C-terminal portion of TFPI-2 consists of a highly conserved cluster of positively
charged amino acids which may point to an antimicrobial activity. Thus a number of selected C-terminal TFPI-2 derived
peptides from different species were synthesized and it was found that all of them exert antimicrobial activity against E.
coli and P. aeruginosa. The peptide-mediated killing of E. coli was enhanced in human plasma, suggesting an
involvement of the classical pathway of the complement. Under in vitro conditions the peptides displayed
anti-coagulant activity by modulating the intrinsic pathway of coagulation and in vivo treatment with the
mouse derived VKG24 peptide protects mice from an otherwise lethal LPS shock model.
Conclusions: Our results suggest that the evolutionary conserved C-terminal part of TFPI-2 is an interesting
agent for the development of novel antimicrobial therapies.
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Background
In response to pathogenic microorganisms, host organ-
isms have evolved a diverse range of defense mechanisms,
starting from simple mechanical barriers to complex
immune systems. In these processes, blood coagulation,
complement cascades and antimicrobial peptides are
central to host defense and many components of these
systems are evolutionary conserved [1]. The crosstalk be-
tween the coagulation and complement systems is essen-
tial for the clearance of the infection. Together they have a
dual role of immobilization and destruction of invading
bacteria in addition to preventing the loss of body fluids.
Coagulation factors, apart from their primary role of
maintaining hemostasis, are also involved in killing of
bacteria and immunomodulation, such as thrombin [2],
kininogen [3], protein C inhibitor [4], fibrinogen [5, 6], an-
tithrombin [7], TFPI-1 [8], and TFPI-2 [9, 10]. These pro-
teins may explore their activities either as intact molecules
or after proteolysis. Often they execute their host defense
functions by killing the intruder or by triggering immuno-
modulatory reactions. Many well-characterized antimicro-
bial peptides have recently been found to exhibit also
multifaceted immunomodulatory activities, such as re-
ported for LL-37 [11, 12] and some antimicrobial peptides
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have been described to be involved in angiogenesis, chemo-
taxis, and wound-healing [11]. These biological properties
suggest that host defense peptides may have a clinical po-
tential also in disorders where targeting of inflammatory
pathways is beneficial, such as in sepsis [11, 13].
Tissue factor pathway inhibitor 2 (TFPI-2) consists of
a highly negatively charged N-terminal region, three
tandemly linked Kunitz-type domains, and a highly posi-
tively charged C-terminus [14, 15]. The molecule is
synthesized and secreted by many cells, including skin fi-
broblasts, endothelial cells (ECs), smooth muscle cells
(SMCs), dermal fibroblasts, keratinocytes, monocytes,
macrophages and syncytiotrophoblasts [16, 17]. In vitro,
TFPI-2 is a weak inhibitor of coagulation induced by the
TF-VII complex, while it targets a wide range of proteases
such as trypsin, chymotrypsin, plasmin, MMPs, factor XIa
and plasma kallikrein [18, 19]. Stimulation of human um-
bilical vein endothelial cells with inflammatory mediators
such as PMA, LPS, or TNF-α significantly increases TFPI-
2 expression [17]. Analogously, in a murine model, TFPI-2
expression is dramatically upregulated in the liver upon
LPS stimulation [20]. Notably, it has been shown that pro-
teases such as ADAMTS1, plasmin and thrombin can
process TFPI-2 at its C-terminal end in in vitro experi-
ments [21]. We previously reported an undisclosed host
defense function of the C-terminal region of TFPI-2
[9, 10]. TFPI-2 as well as the C-terminal peptides of
the molecule were detected in wounds from patients
and were found in complex with the bacteria and fibrin.
Correspondingly, human TFPI-2 was degraded in vitro by
human neutrophil elastase, leading to the generation of C-
terminal TFPI-2 fragments. These fragments were then
found to bind to various bacterial surfaces, kill gram-
negative bacteria, through membrane lysis, and boost
complement activation, including formation of the mem-
brane attack complex (MAC) and antimicrobial C3a. In a
therapeutic context, the peptide significantly reduced
mortality either as a monotherapy, or in combination with
ceftazidime E. coli and P. aeruginosa sepsis models. We
therefore hypothesized that TFPI-2 C-terminal derived
peptides may have an important function in the host
defense to infection, thus they may be interesting agents
for drug development.
Results
Phylogenetic and sequence analysis of the TFPI-2
C-terminal part from different species
A phylogenetic tree was constructed with C-terminal
TFPI-2 sequences from 72 vertebrate organisms, using
neighbor-joining method with 1000 bootstrap repeats,
resulting in distinct groups (Fig. 1). The remainder of
TFPI-2 and full length protein are more conserved than
the C-terminal region, at first suggesting that the C-
terminal region has not been under evolutionary pressure
Fig. 1 Phylogenetic tree analysis of the C-terminal region of TFPI-2
from vertebrates. Phylogenetic tree from 72 vertebrate TFPI-2 species
was constructed using Neighbour-Joining tree with 1000 bootstrap
replications on MEGA6
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(Additional file 1: Figure S1). Even though the TFPI-2
amino acid length varies among the species, many other
conserved regions were observed among the species (data
not shown). Interestingly, the multiple sequence align-
ment of the C-terminal antimicrobial peptide region is not
fully conserved (Fig. 2). Importantly however, even though
the C-terminal region was not well conserved, the net
positive charge is preserved, with a charge ranging from
+7 to +14 (Table 1). This suggests an important role of
the charge and points towards putative antimicrobial
activity where charge rather than the exact amino acid
sequence is essential.
Antimicrobial activities of TFPI-2 C-terminal derived
peptides
Having identified the C-terminal region of TFPI-2, we
next wished to investigate whether other vertebrate de-
rived peptides retain similar bactericidal activity compared
to the human peptide. The antimicrobial properties of the
C-terminal TFPI-2 derived peptides from different verte-
brates were assessed using radial diffusion assay against
gram-negative bacteria E. coli and P. aeruginosa (Fig. 3).
These species included primates (human and gorilla), ro-
dents (mouse), birds (turkey and chicken), reptiles (alliga-
tor and turtle), amphibians (frog) and fishes (shark and
zebra fish). We also noted that all vertebrate peptides
displayed antimicrobial activities at concentrations of
100 μM against both bacteria. In consensus with the hu-
man peptide, we investigated if also other vertebrate-
derived peptides display enhanced bactericidal activity in
presence of plasma. To this end, the peptides were incu-
bated at varying concentrations with E. coli in presence of
physiological buffer containing 20 % human citrate
plasma, since this E. coli strain is complement sensitive. In
concordance with previous data, all vertebrate peptides
displayed enhanced bactericidal activity against E. coli.
Complete bacterial killing was observed at a concentration
of 1 μM in human plasma, which is due to boosting com-
plement activation, whereas higher concentrations of the
peptides were required for their direct antimicrobial activ-
ity as seen from incubating the peptide in presence of buf-
fer (Fig. 4). The growth of bacteria in buffer is slower than
in citrated plasma, but the peptide-mediated killing in
buffer is still less efficient than in citrated plasma.
Effect of TFPI-2 derived peptides on blood coagulation/
intrinsic pathway of coagulation
Previously, it was shown that the human TFPI-2 derived
peptide EDC34 blocks the intrinsic pathway of coagula-
tion in both human and murine plasma [22]. Based on
these findings we investigated the anticoagulant activity
of the vertebrate-derived TFPI-2 peptides by determin-
ing the prolongation of activated partial thromboplastin
time (aPTT). As shown in Fig. 5a, all peptides effectively
prolonged the normal clotting time on aPTT by more
than 100 s when applied at a concentration of 50 μM.
We further noted that all vertebrate-derived anticoagu-
lant peptides tested are non-hemolytic at 60 μM and
thus have potential to be used in therapeutic applica-
tions (Fig. 5b).
Mouse C-terminal TFPI-2 derived VKG24 peptide provides
protection against septic shock
Given the observed effects of the TFPI-2 C-terminal
peptides, we made an attempt to find out whether these
peptides are of therapeutic importance. To test whether
the endogenous C-terminal TFPI-2 region is important
in host defense, the mouse peptide VKG24 was chosen
for a murine in vivo model. In vitro, VKG24 peptide dis-
played potent antimicrobial and anti-coagulant activities
in mouse plasma (Additional file 2: Figure S2). Thus, the
in vivo efficiency of VKG24 peptide was evaluated in a
standardized mouse model of endotoxin-induced shock
[22]. A dramatic improvement in the survival rate of the
animals was seen after treatment with the peptide
(~25 mg/kg body weight) (Fig. 6a). Peptide-treated ani-
mals started regaining their weight from day three
(Fig. 6b). Previous studies have shown that
thrombocytopenia is as an important indicator for the se-
verity of sepsis and disseminated intravascular coagulation
[23]. Therefore, activation of the intrinsic and extrinsic co-
agulation pathways was measured in citrate plasma of
LPS-injected mice that received a VKG24 injection or
were left untreated. The treatment showed significantly
decreased coagulation aPTT and PT times in LPS chal-
lenged mice, indicating that the peptide reduced con-
sumption of coagulation proteins (Fig. 6c). The levels
were completely normalized in the survivors after
seven days. Analyses of the cytokine profile 24 h after
LPS injection showed significant reduction of IL-6,
MCP-1, IFN-γ and IL-10, respectively (Fig. 6d). Thus,
the results demonstrate that the mouse VKG24 pep-
tide exerts potent immunomodulatory activity.
Discussion
In the present study we aimed to study the host defence
and immunomodulatory activities of the vertebrate C-
terminal epitope of TFPI-2. Sequence analysis of this re-
gion in different vertebrate species showed that the exact
amino acid sequence was not well conserved, whereas
the net positive charge appeared to be preserved. These
findings suggest an essential function of the charge. It
can be speculated that there has been an evolutionary
pressure to maintain the positive charge in the C-
terminal region, as this is important in the host defence
against bacterial pathogens. Within the last years, TFPI-
2 has attracted increasing attention because of its ubi-
quitous presence, which leads to the deposition in a
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Fig. 2 Sequence homology of the C-terminal region of TFPI-2. ClustalW multiple sequence alignment of TFPI-2 where identical and similar amino
acids in all sequences are highlighted in black and grey shaded, respectively
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Table 1 Multiple sequence alignment of vertebrate TFPI-2 C-terminal region showing identical and similar amino acids
Entry & name Latin & name English & name Protein & sequence Net & charge
MAMMALS
P48307 Homo sapiens Human CAKALKKKKKMPKLRFASRIRKIRKKQF 14
H2QUX8 Pan troglodytes Chimpanzee CAKALKKKKKMPKLRFASRIRKIRKKQF 14
U3ENJ1 Callithrix jacchus White-tufted-ear marmoset CEKALKKQRKMPKIPFSNRNLKIWKKQF 9
F7CWN2 Macaca mulatta Rhesus macaque CAKALKRKKKIPKFRFASRIRKIRKKQF 14
XP_003896360.1 Papio anubis Olive baboon CAKALKRKKKIPKFRFASRIRKIRKKQF 14
H2PMX0 Pongo abelii Sumatran orangutan CAKALRKKKKMPKLRFASRIRKIRKKQF 14
G3QPC8 Gorilla gorilla gorilla Western lowland gorilla CAKALKRKKKMPKLRFASRIRKIRKKQF 14
XP_008067041.1 Tarsius syrichta Philippine tarsier CVKVLKKKTKVPKLLFANRRRKMQKKQF 12
H0XT57 Otolemur garnettii Small-eared galago CAKALKKEKNKTMPKLPFVNRILKVRK 9
O35536 Mus musculus Mouse CVKGWKKPKRWKIGDFLPRFWKHLS 7
XP_005363735.1 Microtus ochrogaster Prairie Vole CVKAPKKPKKRKTGSGFRIRTKPRRWTP 12
XP_004602345.1 Sorex araneus European shrew CANAMKKYKIKKLQRRHPSRRRSLKIKK 13
EDL84392.1 Rattus Norvegicus Brown Rat CVKALKKPKRRKIGDFLPRFWKLRS 9
XP_010601797.1 Fukomys damarensis Damaraland Mole Rat CEKAYKRGKRKTQKPPFSIKRPKSWRKR 12
H0VU83 Cavia porcellus Guinea pig CEKAYKRGKRKTQIPPFSIRRPKSWKKV 10
XP_007522577.1 Erinaceus europaeus Western European Hedgehog CAKASKKGKIRKMPRGILVNRRETYKKK 11
XP_011361893.1 Pteropus vampyrus Large Flying Fox CIKALKKKQNKKMPKILFVNRNLKMQKK 11
G1PX03 Myotis lucifugus Little brown bat CMKALRKKINKKMPRFFFPDRRRKLQKK 12
XP_006834353.1 Chrysochloris asiatica Cape Golden Mole CTLALKKENNKKMRKSFITNRRLKMRKR 11
XP_008569808.1 Galeopterus variegatus Sunda flying lemur CAKVKKGKNKKILKFPFVVRNLKFRKKK 13
XP_004475751.1 Dasypus novemcinctus Nine-banded Armadillo CENALKKEKKKKIPKGFFAIRRPKIQKK 10
W5NS10 Ovis aries Sheep CVKALKKEKNKKMPRLLFANRRLKIKKQ 11
M3X7K4 Felis silvestris catus Cat CVKALKKEKNKKMPKLFFANRRLKIWKR 11
G3THG9 Loxodonta africana African elephant CTKALKKKKKIQKPLFANRSPQIRK 10
F1SFC1 Sus scrofa Pig CVKALKKEKKMPRLLLASRRLKIKKKQF 11
E2RBF0 Canis familiaris Dog CVKALKKERNKKMTKLSLVNRRLKNWKK 11
G1MHA9 Ailuropoda melanoleuca Giant panda CVKGSRNEKNMQLLKTVFPRRRLKTYKN 8
Q7YRQ8 Bos taurus Bovine CVKALKKEKNKKMPRLLLANRRLKIKKK 12
XP_008684473.1 Ursus maritimus Polar bear CVKGSRKEKNMKLLKTVFPGRRLKTYKK 10
XP_008542988.1 Equus przewalskii Przewalski’s horse CAKGLKKKKNKKMKTLFLANRSLKLQKK 12
XP_007938042.1 Orycteropus afer afer Aardvark CVGFSLKKEKRKKIQKVLFANRRLKIRK 11
XP_007076762.1 Panthera tigris altaica Amur Tiger CVKALKKEKNKKMPKLFFANKRLKIWKR 11
XP_004431409.1 Ceratotherium simum simum Southern White Rhinoceros CTKALKKKKNRKMPKLFLANRSLKLRRK 13
XP_004386213.1 Trichechus manatus latirostris Florida manatee CAKALKKKKKKIRKFVLASRSLKLQKKQ 13
XP_006733001.1 Leptonychotes weddellii Weddell seal CIKAVRKQKDKKTPKIVFAHRRVKTWKK 11
XP_007450700.1 Lipotes vexillifer Yangtze River dolphin CVKALKKGKNKKMPKLLFASRRLKIKKK 13
XP_004265641.1 Orcinus orca Killer Whale CVKALKKGKNKKMPKLLFASRRLKIKKK 13
BIRDS
XP_010710984 Meleagris gallopavo Wild Turkey CKKGSQKPTISKPRNLLRRKMMRKLIKK 12
XP_009328855.1 Pygoscelis adeliae Adélie penguin CRKGTQKPRINKPMNVFRRKVMRKLIKK 12
XP_010560815 Haliaeetus leucocephalus Bald eagle CRKAGTQKPRINKPTNVFRRKMMRKLIK 11
XP_005228880.1 Falco peregrinus Peregrine falcon CRKGTQKPRINKPANVFRRKMMRKLTKK 12
XP_009934468.1 Opisthocomus hoazin Hoatzin CRKGTEKPRINKPTNVFRRKMMRKLVKK 11
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variety of tissues and particularly in the extracellular
matrix. This likely reflects its potential as a central regu-
lator of multiple biological processes involving the con-
trol of inflammatory reactions, matrix protease activity,
coagulation, angiogenesis, and tumour growth. In previ-
ous studies we found that the proteolysis of human
TFPI-2 generates C-terminal fragments, both in vivo
and in vitro after digestion with neutrophil elastase.
These findings are of importance in the context of pro-
teolysis of TFPI-2 and possible release of bioactive host
defence fragments [9, 10]. Notably, the observed gener-
ation of C-terminal fragments of TFPI-2 are very similar
to that seen with TFPI-1, suggesting that the same
cleavage sites is used by plasmin and thrombin to gener-
ate the C-terminal part of TFPI-1. Interestingly, previous
data on TFPI-1 and TFPI-2 revealed that the release of
C-terminal peptides may exert similar complement
boosting effects [8–10]. It is also notable that the C-
terminal peptide of TFPI-1, GGL27, and TFPI-2, EDC34
prolongs aPTT, thus further illustrating a functional
overlap between the two TFPI proteins. In a broader
perspective, a picture thus emerges; suggesting that C-
terminal fragments from both TFPI-1 and TFPI-2 may
be released during inflammation and infection, serving
as modulators of both antimicrobial activity and coagu-
lation. So far, available structural and functional data
Table 1 Multiple sequence alignment of vertebrate TFPI-2 C-terminal region showing identical and similar amino acids (Continued)
XP_009893654.1 Charadrius vociferus Killdeer CRKAGAQKPRIDKPTNVFRRKMMRKLIK 10
XP_009639692.1 Egretta garzetta Little egret CRKGTEKPGINKPMNVFRRKMMRKLTKK 10
XP_009672625.1 Struthio camelus australis Ostrich CRKGSEKPRINKPANLLRRKMMRKLIKK 11
XP_009464906.1 Nipponia nippon Crested Ibis CRKGTEKPRINKPTNVFRRKMMRKLIKK 11
XP_009084577.1 Serinus canaria Atlantic canary CRKAGNQKPSINKPTNLSRRKIVRKLKK 11
XP_008919443.1 Manacus vitellinus Golden-collared manakin CRKGTQKPRINKPMSVSRRKIMRKLIKK 12
XP_008492487.1 Calypte anna Anna’s hummingbird CRKAGTQKPKINKPVNGVRRKMMIKLIK 11
XP_005518860.1 Pseudopodoces humilis Ground tit CGKGNQKLRINKPTNVSRRKIVRKLIEK 9
XP_005152979.1 Melopsittacus undulatus Budgerigar CRKGTQKPGINKPMNVFRRKMMRKLVKK 11
XP_005041216.1 Ficedula albicollis The collared flycatcher CRNAGNQKLRINKPTNVSRRKLVRKLIK 10
XP_005010988.1 Anas platyrhynchos Mallard CGKAGSQKPAMKKSTDVFRRKMMRKLIK 9
XP_418662.2 Gallus gallus Chicken CRKGSQKPTINKSRSLLRRKMMRKLIKK 12
XP_005418689.1 Geospiza fortis Medium ground finch CRNGNQKPGINKPTNLSRRKIVRKLKKK 11
XP_005480303.1 Zonotrichia albicollis White-throated Sparrow CRNAGNQKPAINKPANLSRRKIVRKLKK 10
REPTILES
XP_005308608.1 Chrysemys picta bellii Western painted turtle CKKAGSKKSSFKKSRNKLPKTMRKLPEK 11
XP_006258519.1 Alligator Mississippiensis American Alligator CRKAGNKKPRIKPKSKVMRKMMRKLQKN 13
AMPHIBIANS
Q5FVY6 Xenopus tropicalis Western clawed frog CKKGSKRPRNRNRIRVPRIQS 9
FISHES
XP_010889816.1 Esox lucius The northern pike CAKAGKLWKTKNPVTKTAMMKIPKKRSR 10
XP_010739844.1 Larimichthys crocea Croceine croaker CAKGGKKYKRQGKGRRMRRYRNNNITFL 11
XP_008419957.1 Poecilia reticulata Guppy CVRGPKRHSSHGKLRRLRQNRNNHLPLH 8
XP_008329541.1 Cynoglossus semilaevis Cynoglossus CVKGEKKHTGQGMIRRLRRNKNNSIFVV 7
XP_008287494.1 Stegastes partitus Bicolor damselfish CVKGAKKQTGQGKGRRMRRNRHNHITFL 9
XP_007259866.1 Mexican tetra Astyanax mexicanus CARKSKPGKMRRKLIPRKPERRI 10
C3KHI5 Anoplopoma fimbria Sablefish CVTGRKHTIQSKGRRLRRNRINRITFRQ 10
Q1WCN6 Danio rerio Zebrafish CGSKRWSPTKKSVRVSKQYLRRVKPQPS 9
I3JXJ8 Oreochromis niloticus Nile tilapia CAKGWKKHPGRGKILRSRKNRKLVTFLQ 10
XP_003969359.1 Takifugu rubripes Japanese Puffer CVRGRKIRTREGKTNPLRRNRNNRITFM 9
XP_004073873.1 Oryzias latipes Japanese Rice Fish CLKGAKKHTGLKGRDRLMKRNKKTRFMA 10
XP_010772945.1 Notothenia coriiceps Black Rock Cod CARRGKKLTSQVKGRRKRRNRNNRITFL 12
XP_007903512.1 Callorhinchus milii Australian Ghostshark CQKRNKKKTSQKYPTASITRKVVKKNSR 11
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separate the C-terminal TFPI-2 peptides from the group
of classical amphipathic antimicrobial peptides, such as
the helical cathelicidin peptide LL-37 as well as defen-
sins. Indeed, the EDC34 show a similarity to some linear
peptides of low helical content, such as antimicrobial
peptides derived from growth factors [24] as well as hu-
man kininogen, all displaying mostly random coil con-
formation in buffer and at lipid bilayers, the interactions
dominated by electrostatic interactions [25].
It remains to be investigated whether TFPI-2 peptides
may have similar actions as those reported here, al-
though the absence of a marked boosting of activity in
plasma suggests that complement interactions are char-
acteristic for the TFPI-peptides. The detailed mode of
action of these peptides remains to be explored, but it
seems that they are involved in interactions with C1q
and/or other molecules that can initiate the classical
pathway of complement and lead to the formation of
C3a or a MAC complex. Contact activation, involving
degradation of human kininogen, and release of vaso-
active bradykinin has been reported during various in-
fective processes including sepsis [26, 27]. The finding
that EDC34 inhibited contact activation in vitro is of im-
portance, since a generalized activation of the system
can be deleterious.
From a clinical perspective, many opportunistic bac-
teria can cause both localized and systemic infections
and are responsible for considerable mortality or mor-
bidity in patients suffering from burn wound infec-
tions, pneumonia, cystic fibrosis, intra-abdominal
infections, chronic ulcers, and sepsis. Our results
show a direct antimicrobial activity of the TFPI-2
peptide derived from different vertebrates species. The
potent antimicrobial activity of these peptides was
paired with boosting of complement activation and a
modulation of the coagulation cascade. In vivo, VKG24
administration after LPS challenge protects mice and also
significantly reduced aPTT and PT time. Therefore, our
findings that VKG24 is able to significantly reduce LPS
induced shock is particularly relevant, and implies a thera-
peutic potential for VKG24. The protective effect of
mouse VKG24 in infections caused by Gram-negative
pathogens may also apply to other vertebrate TFPI-2 C-
terminal peptides.
Conclusions
Several therapeutic strategies to combat severe infec-
tions including sepsis are based on supplementation
of antibiotics with molecules exerting anti-coagulant
and anti-inflammatory actions [28]. The dual effects
of these natural peptides, for example the mouse de-
rived VKG24 peptide, that can block contact activa-
tion and boost complement activation, thus represent,
to our knowledge, a novel treatment concept, which
could enable complement mediated bacterial clearance
while inhibiting the deleterious effects of excessive




Indicated peptides (Additional file 3: Table S1) were syn-
thesized by Ontores (Shanghai, China). The purity (>98 %)
Fig. 3 Antimicrobial activities of TFPI-2 C-terminal derived peptides from different species. For determination of antimicrobial activities, E. coli ATCC
25922 and P. aeruginosa ATCC 27853 (4 × 106 cfu) were inoculated in 0.1 % TSB agarose gel. Each 4 mm-diameter well was loaded with 6 μl of peptide
(at 100 μM). The zones of clearance (in mm) correspond to the inhibitory effect of each peptide after incubation at 37 °C for 18–24 h (mean values are
presented, n = 3). A control with buffer only yielded no inhibition zone
Kasetty et al. BMC Microbiology  (2016) 16:129 Page 7 of 12
of these peptides was confirmed by mass spectral analysis
(MALDI-ToF Voyager).
Microorganisms
The bacterial isolates E. coli ATCC 25922 and P. aerugi-
nosa ATCC 27853 were obtained from the American
Type Culture Collection.
Radial diffusion assay (RDA)
Essentially as described earlier, bacteria were grown to
mid-logarithmic phase in 10 ml of full-strength (3 % w/v)
trypticase soy broth (TSB) (Becton-Dickinson, Cockeysville,
MD). The microorganisms were then washed once with
10 mM Tris, pH 7.4. Subsequently, 4 × 106 bacterial colony
forming units (cfu) were added to 15 ml of the underlay
Fig. 4 Activities of TFPI-2 C-terminal derived peptides in human plasma. The bactericidal activity of TFPI-2 peptides was assessed in physiological
buffer conditions using viable count analysis. a–e Bacteria E. coli ATCC 25922 were grown to mid-logarithmic phase and incubated with varying
concentrations of peptides corresponding to sequences found in mammals, birds, reptiles, frog and fish species. Peptides were used in buffer
containing 0.15 M NaCl, 10 mM Tris, pH 7.4 alone, or in presence of 20 % human plasma. The antimicrobial activity was determined by plating
serial dilution of bacteria on TH agar plates and number of cfu was counted after overnight incubation. All investigated peptides showed dose
dependent bactericidal activity and 100 % bacterial killing was achieved in all cases at 1 μM concentration
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agarose gel, consisting of 0.03 % (w/v) TSB, 1 % (w/v)
low electroendosmosis type (EEO) agarose (Sigma, St
Louis, MO) and 0.02 % (v/v) Tween 20 (Sigma). The
underlay was poured into a Ø 144 mm petri dish.
After agarose solidification, 4 mm-diameter wells were
punched and 6 μl of test sample was added to each
well. Plates were incubated at 37 °C for 3 h to allow
diffusion of the peptides. The underlay gel was then
covered with 15 ml of molten overlay (6 % TSB and
1 % Low-EEO agarose in distilled H2O). Antimicrobial
activity of a peptide is visualized as a zone of clearing
around each well after 18–24 h of incubation at 37 °C.
Viable count analysis (VCA)
E. coli were grown to mid-exponential phase in Todd-
Hewitt (TH). Bacteria were washed and diluted in
10 mM Tris, pH 7.4 either alone or with 20 % human or
mouse (BALB/c) citrate-plasma. Bacterial (2 × 106 cfu/ml)
were incubated in 50 μl, at 37 °C for 1 h with the C-
terminal TFPI-2 derived peptides at the indicated concen-
trations. Serial dilutions of the incubation mixture were
plated on TH agar, followed by incubation at 37 °C over-
night and cfu determination.
LPS animal model
Male/female balb/c mice (8 weeks, 21 ± 5 g) were injected
intraperitoneally (i.p.) with 10 mg E. coli 0111:B4 LPS
(Sigma) per kg of body weight. Thirty minutes after LPS
injection, 0.5 mg VKG24 (25 mg/kg) or PBS buffer alone
(control) were injected i.p. into the mice. Status and
weight were monitored daily for seven days. Mice where
immobilization and/or shaking was observed were eutha-
nized by an overdose of isoflurane (Abbott) and counted
as non-survivors. For determination of cytokine levels in
mouse plasma, animals were sacrificed 24 h after LPS
injection. The blood was collected immediately by cardiac
puncture into citrate tubes.
Cytokine assay
Cytokines IL-6, IL-10, MCP-1, INF-γ and TNF-α were
measured in plasma from mice infected by E. coli
LPS (with or without peptide treatment) using the
Cytometric bead array; mouse inflammation kit (Becton
Dickinson AB) according to the manufacturer’s instruc-
tions. All plasma samples were stored at −80 °C before
the analysis.
Hemolysis assay
EDTA-blood was centrifuged at 800 × g for 10 min,
where after plasma and buffy coat were removed. The
erythrocytes were washed three times and resuspended
in PBS, pH 7.4 to get a 5 % suspension. The cells were
then incubated with end-over-end rotation for 60 min at
37 °C in the presence of peptides (60 μM). Triton X-100
(Sigma) 2 % served as positive control. The samples
were then centrifuged at 800 × g for 10 min and the
supernatant was transferred to a 96 well microtiter plate.
The absorbance of hemoglobin release was measured at
540 nm and expressed as percentage of Triton X-100
induced hemolysis.
Phylogenetic and sequence homology analyses
Various vertebrate TFPI-2 amino acid sequences, which
are presently available, were retrieved from the NCBI,
Fig. 5 Anticoagulant effects of TFPI-2 derived peptides. a The activated
partial thromboplastin time (aPTT) was determined by addition of
buffer or 50 μM of different vertebrate TFPI-2 derived peptides to
human plasma. Data are presented as clotting time in seconds;
values are mean ± SD (n = 3). b Human erythrocytes were incubated
with 60 μM of vertebrate TFPI-2 derived peptides. The hemoglobin
release was measured at λ 540 nm and hemolysis was indicated in
percentage, Triton X-100 treated sample being used a positive control
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Ensembl and Uniprot. These sequences were aligned
using Blosum 69 protein weight matrix settings using
BioEdit software (Ibis Biosciences, Carlsbad, CA). In-
ternal adjustments were made taking the structural
alignment into account utilizing the ClustalW interface.
Neighbor-joining method was used for phylogenetic tree
construction, and the reliability of each branch was
assessed using 1000 bootstrap replications using Mega-6.
Clotting assays
All clotting times were analyzed using a coagulometer
(Amelung, Lemgo, Germany). For determination of acti-
vated partial thromboplastin time (aPTT), 100 μl of a
kaolin-containing solution (Technoclone) was added to
the 100 μl of fresh citrate plasma or citrate plasma pep-
tide mix and incubated at 37 °C for 200 s before clot
formation was initiated by adding 100 μl of 30 mM fresh
CaCl2 solution. For detection of prothrombin time (PT,
thromboplastin reagent (Trinity Biotech)) 100 μl of fresh
citrate plasma were incubated 60 s at 37 °C before clot for-
mation was initiated by adding 100 μl of clotting reagent.
Statistical analysis
Values are shown as mean with SEM. For statistical
evaluation of two experimental groups, one-way with
Tukey’s multiple comparisons post-test was used and for
comparison of survival curves the Mantel-Cox’s test.
Viable count and radial diffusion assay data are pre-
sented as mean with SD. All statistical evaluations were
performed using the GraphPad Prism software 6.0
with *p- < 0.05, **p- < 0.01, *** < 0.001, ****p < 0.0001 and
ns = not significant.
Fig. 6 Treatment of LPS-induced septic shock mice with a mouse TFPI-2 derived peptide. Septic shock in Balb/c mice was induced by i.p.
injection of 10 mg/kg E. coli LPS. Thirty minutes after LPS injection, VKG24 (0.5 mg/mouse or ~25 mg/kg body weight) or PBS was administrated
i.p. a Mouse TFPI-2 derived peptide significantly increased survival of mice. Survival of mice was monitored for 7 days (only the first 96 h is shown in
the figure). Statistical comparisons of survival curves were performed using the Mantel-Cox’s test. ***P ≤ 0.0003. b Weight was determined daily.
c Clotting times of aPTT and PT was measured in citrate plasma 24 h after LPS injection (n = 8). d The indicated cytokines were analyzed
in plasma 24 h after LPS injection (n = 8). Statistical analysis for C-D, one-way ANOVA with Tukey’s multiple comparisons post-test was
used. **P ≤ 0.003, ****P ≤ 0.0001
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Additional files
Additional file 1: Figure S1. Phylogenetic tree analysis of full-length
and reminder protein except C-terminal TFPI-2 from vertebrates. Phylogenetic
tree from 72 vertebrate TFPI-2 species was constructed using Neighbour-
Joining tree with 1000 bootstrap replications on MEGA6. (PDF 54 kb)
Additional file 2: Figure S2. Activities of TFPI-2 C-terminal derived
peptides in mouse plasma. (Left) The bactericidal activity of mouse VKG24
peptide was assessed in physiological buffer conditions using viable count
analysis. E. coli ATCC 25922 were grown to mid-logarithmic phase and
incubated with varying concentrations of peptide. The antimicrobial activity
was determined by plating serial dilutions of bacteria on TH agar plates and
number of cfu was counted after overnight incubation. (Right) The activated
partial thromboplastin time (aPTT) was determined by addition of buffer or
50 μM of VKG24 peptide to mouse plasma. Data are presented as clotting
time in seconds; values are mean ± SD (n = 3). (PDF 32 kb)
Additional file 3: Table S1. Selected vertebrate TFPI-2 C-terminal peptides
showing sequence entry name, species, sequence, charge and hydrophobicity.
(PDF 73 kb)
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